Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 452-463

  Rupanagudi, Khader Valli ^a   Kulkarni, Onkar P ^a   Lichtnekert, Julia ^a   Darisipudi, Murthy Narayana ^a   Mulay, Shrikant R ^a   Schott, Brigitte ^b   Gruner, Sabine ^b   Haap, Wolfgang ^b   Hartmann, Guido ^b   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN S; CATHEPSIN S INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RO 5461111; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CATHEPSIN; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; PROLINE; RO5461111;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HYPERGAMMAGLOBULINEMIA; IN VITRO STUDY; IN VIVO STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PLASMA CELL; PROTEIN EXPRESSION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; B-LYMPHOCYTES; BLOTTING, WESTERN; CATHEPSINS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; PROLINE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84921366294     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203717     Document Type: Article

References (30)

1. Rahman A, Isenberg DA. Systemic Lupus Erythematosus. N Eng J Med 2008;358:929-39.
2. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013;24:1357-66.
3. Kulkarni OP, Anders H-J. Lupus nephritis. How latest insights into its pathogenesis promote novel therapies. Curr Opin Rheumatol 2012;24:457-65.
4. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol 2012;30:429-57.
5. Glassock RJ. Human idiopathic membranous nephropathy - a mystery solved? N Engl J Med 2009;361:81-3.
6. Anders HJ. Toll-like receptors and danger signaling in kidney injury. J Am Soc Nephrol 2010;21:1270-4.
7. Gupta S, Singh RK, Dastidar S, et al. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin Ther Targets 2008;12:291-9.
8. Riese RJ, Wolf PR, Brömme D, et al. Essential role for Cathepsin S in MHC Class II associated invariant chain processing and peptide loading. Immunity 1996;4:357-66.
9. Driessen C, Bryant RAR, Lennon-Duménil A-M, et al. Cathepsin S controls the trafficking and maturation of Mhc Class II molecules in dendritic cells. J Cell Biol 1999;147:775-90.
10. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76:287-99.
11. Roche PA, Marks MS, Cresswell PJ. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991;354:392-4.
12. Riese RJ, Mitchell RN, Villadangos JA, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Inves 1998;101:2351-63.
13. Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci 1988;85:3975-9.
14. Shi GP, Munger JS, Meara JP, et al. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992;267:7258-62.
15. Baugh M, Black D, Westwood P, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 2011;36:201-9.
16. Deschamps K, Cromlish W, Weicker S, et al. Genetic and pharmacological evaluation of Cathepsin S in a mouse model of asthma. Am J Respir Cell Mol Biol 2011;45:81-7.
17. Saegusa K, Ishimaru N, Yanagi K, et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002;110:361-9.
18. Kala M, Chen CR, McLachlan SM, et al. Cathepsin S is not crucial to TSHR processing and presentation in a murine model of Graves' disease. Immunology 2005;116:532-40.
19. Stoeckle C, Quecke P, Rückrich T, et al. Cathepsin S dominates autoantigen processing in human thymic dendritic cells. J Autoimmun 2012;38:332-43.
20. Patole PS, Pawar RD, Lichtnekert J, et al. Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun 2007;29:52-9.
21. Austin HA III, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: identi fication of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-95.
22. Shi G-P, Villadangos JA, Dranoff G, et al. Cathepsin S required for normal MHC Class II peptide loading and germinal center development. Immunity 1999;10:197-206.
23. Allam R, Pawar RD, Kulkarni OP, et al. Viral 5′-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur J Immunol 2008;38:3487-98.
24. Kulkarni O, Pawar RD, Purschke W, et al. Spiegelmer Inhibition of CCL2/MCP-1 Ameliorates Lupus Nephritis in MRL-(Fas)lpr Mice. J Am Soc Nephrol 2007;18:2350-8.
25. Lech M, Skuginna V, Kulkarni OP, et al. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J Pathol 2010;220:596-607.
26. Lech M, Susanti HE, Rommele C, et al. Quantitative expression of C-type lectin receptors in humans and mice. Int J Mol Sci 2012;13:10113-31.
27. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007;130:25-35.
28. Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol 2004;5:943-52.
29. Victora GD, Dominguez-Sola D, Holmes AB, et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 2012;120:2240-8.
30. Liu Z, Davidson A. Taming lupus - a new understanding of pathogenesis is leading to clinical advances. Nat Med 2012;18:871-82.